SEC Filing Analysis: UNITED THERAPEUTICS Corp (UTHR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Founder, Chairperson, and CEO of United Therapeutics has filed a notice of a proposed sale of 4,000 shares, valued at approximately $1.9 million, under a pre-established 10b5-1 trading plan.
• Market Impact: Neutral. The transaction is immaterial relative to the company's market capitalization and is part of a pre-scheduled plan, mitigating any negative sentiment.

Company Information

Field	Value
Company	UNITED THERAPEUTICS Corp
Ticker Symbol	UTHR
CIK	0001082554
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	ROTHBLATT MARTINE A
CIK	0001106578
Title/Position	FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-24 (Approximate)
Transaction Code	Not Applicable (Proposed Sale)
Security Type	COMMON
Shares Involved	4,000
Price Per Share	~$470.78 (implied)
Total Value	$1,883,114
Shares Owned After	Not Stated
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,883,114
% of Market Cap	0.0094%
Shares Transacted	4,000
% of Shares Outstanding	0.0089%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $20.08 billion, a sale of less than $2 million is financially insignificant.
• Transaction Significance: The sale represents a negligible percentage of both market capitalization and shares outstanding, falling well below the thresholds for moderate or high significance. It is a routine transaction for an executive of this stature.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is of a very small size and is being conducted under a 10b5-1 trading plan, which was adopted on May 2, 2025. Such plans are established in advance to allow insiders to sell shares over time for personal reasons, removing the implication that the sale is based on non-public information.

Volume & Sentiment

• Expected Volume Impact: Negligible. The 4,000 shares are unlikely to have a noticeable effect on daily trading volume.
• Sentiment Indicator: Neutral. The market generally views pre-planned 10b5-1 sales by long-tenured executives as non-events.

Additional Context

Transaction Notes

• Special Circumstances: This Form 144 filing is a notice of a proposed sale under a Rule 10b5-1 trading plan. The filing also discloses a consistent pattern of similar-sized sales over the past three months, reinforcing the routine nature of this activity.